Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice

Clinical and Experimental Immunology

Volumn 130, Issue 1, 2002, Pages 25-31

  Kruzel, M L ^a,d   Harari, Y ^a   Mailman, D ^b   Actor, J K ^a   Zimecki, M ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Endotoxaemia; LPS; Sepsis; Septic shock; Systemic inflammatory response syndrome

Indexed keywords

ENDOTOXIN; INTERLEUKIN 10; INTERLEUKIN 6; LACTOFERRIN; LIPOPOLYSACCHARIDE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; ENDOTOXEMIA; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; SEPTIC SHOCK;

ANIMALS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; ENDOTOXEMIA; FEEDBACK; HUMANS; INFLAMMATION MEDIATORS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-10; INTERLEUKIN-6; LACTOFERRIN; LIPOPOLYSACCHARIDES; MICE; MODELS, ANIMAL; NITRIC OXIDE; RESPIRATORY BURST; SHOCK, SEPTIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036379733     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01956.x     Document Type: Article

References (56)

1. Vorland LH. Lactoferrin: a multifunctional glycoprotein. APMIS 1999; 107:971-81.
2. Sanchez L, Calvo M, Brock JH. Biological role of lactoferrin. Arch Dis Child 1992; 67:657-61.
3. Lonnerdal B, Iyer S. Lactoferrin. molecular structure and biological function. Annu Rev Nutr 1995; 15:93-110.
4. Kruzel ML, Harari Y, Chen CY, Castro AG. The gut: a key metabolic organ protected by lactoferrin during experimental systemic inflammation in mice. Adv Exp Med Biol 1998; 443:167-73.
5. Gutteberg TJ, Rokke O, Andersen O, Jorgensen T. Early fall of circulating iron and rapid rise of lactoferrin in septicemia and endotoxaemia: an early defence mechanism. Scand J Infect Dis 1989; 21:709-15.
6. Zagulski T, Lipinski P, Zagulska A, Broniek S, Jarzabek Z. Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. Br J Exp Pathol 1989; 70:697-704.
7. Nebermann L, Dohler JR, Perlick L. Treatment of enterogenic endotoxinemia with lactoferrin in rats. Langenbecks Arch Surg 2001; 386:146-9.
8. Kruzel ML, Harari Y, Chen CY, Castro GA. Lactoferrin protects gut mucosal integrity during endotoxaemia induced by lipopolysaccharide in mice. Inflammation 2000; 24:33-44.
9. Zimecki M & Kruzel M. Protective effect of lactoferrin against LPS-induced endotoxaemia is mediated by IL-10. In: Faist E, ed. Proceedings of the 5th World Conference on Trauma, Shock, Inflammation and Sepsis; Pathophysiology, Immune Consequences and Therapy. Munich, Germany, February 29-March 4. Bologne: Monduzi Editore, 2000: 221-5.
10. Ellison RT III, Giehl TJ, LaForce FM. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect Immun 1988; 56:2774-81.
11. Elass-Rochard E, Legrand D, Salmon V et al. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect Immun 1998; 66:486-91.
12. Zimecki M, Kocieba M, Kruzel M. Immunoregulatory activities of latoferrin in the delayed type hypersensitivity in mice are mediated by a receptor with affinity to mannose. Immunobiol 2002; 205:120-31.
13. Duthille I, Masson M, Spik G, Mazurier J. Lactoferrin stimulates the mitogen-activated protein kinase in the human lymphoblastic T Jurkat cell line. Adv Exp Med Biol 1998; 443:257-60.
14. Zimecki M, Miedzybrodzki R, Mazurier J, Spik G. Regulatory effects of lactoferrin and lipopolysaccharide on LFA-1 expression on human peripheral blood mononuclear cells. Arch Immunol Ther Exp (Warsz) 1999; 47:257-64.
15. Raetz CR, Ulevitch RJ, Wright SD, Sibley CH, Ding A, Nathan CF. Gram-negative endotoxin. an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J 1991; 5:2652-60.
16. Ulevitch RJ & Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995; 13:437-57.
17. Pajkrt D, Doran JE, Koster F et al. Anti-inflammatory effects of reconstituted high-density lipoprotein during human endotoxaemia. J Exp Med 1996; 184:1601-8.
18. Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg 1992; 216:117-34.
19. Deitch EA. Role of bacterial translocation in necrotizing enterocolitis. Acta Paediatr Suppl 1994; 396:33-6.
20. DeMaria E & Dalton JM. Bacterial translocation and the release of endotoxin and cytokines following trauma. In: Sugerman HJ & DeMaria EJ, eds. Cytokines in Trauma and Hemorrhage. Austin, TX: R. G. Landes Company, 1996:43-61.
21. Nadler EP, Upperman JS, Dickinson EC, Ford HR. Nitric oxide and intestinal barrier failure. Semin Pediatr Surg 1999; 8:148-54.
22. Mishima S, Xu D, Lu Q, Deitch EA. Bacterial translocation is inhibited in inducible nitric oxide synthase knockout mice after endotoxin challenge but not in a model of bacterial overgrowth. Arch Surg 1997; 132:1190-5.
23. Sorrells DL, Friend C, Koltuksuz U, Courcoulas A, Boyle P, Garrett M, Watkins S, Rowe MI, Ford HR. Inhibition of nitric oxide with aminoguanidine reduces bacterial translocation after endotoxin challengein vivo. Arch Surg 1996; 131:1155-63.
24. Mishima S, Xu D, Lu Q, Deitch EA. The relationships among nitric oxide production, bacterial translocation, and intestinal injury after endotoxin challenge in vivo. J Trauma 1998; 44:175-82.
25. Gerard C, Bruyns C, Marchant A et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxaemia. J Exp Med 1993; 177:547-50.
26. Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJ, van der Poll T. Proinflammatory effects of IL-10 during human endotoxaemia. J Immunol 2000; 165:2783-9.
27. Murphey ED & Traber DL. Protective effect of tumor necrosis factor-alpha against subsequent endotoxaemia in mice is mediated, in part, by interleukin-10. Crit Care Med 2001; 29:1761-6.
28. Zimecki M, Wlaszczyk A, Wojciechowski R, Dawiskiba J, Kruzel M. Lactoferrin regulates the immune responses in post-surgical patients. Arch Immunol Ther Exp (Warsz) 2001; 49:325-33.
29. Redl H, Bahrami S, Schlag G, Traber DL. Clinical detection of LPS and animal models of endotoxaemia. Immunobiology 1993; 187:330-45.
30. Freise H, Bruckner UB, Spiegel HU. Animal models of sepsis. J Invest Surg 2001; 14:195-212.
31. Fleet JC. A new role for lactoferrin. DNA binding and transcription activation. Nutr Rev 1995; 53:226-7.
32. Granger DL, Taintor RR, Boockvar KS, Hibbs JB Jr. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Meth Enzymol 1996; 268:142-51.
33. Machnicki M, Zimecki M, Zagulski T. Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo. Int J Exp Pathol 1993; 74:433-9.
34. Choe YH & Lee SW. Effect of lactoferrin on the production of tumor necrosis factor-alpha and nitric oxide. J Cell Biochem 1999; 76:30-6.
35. He J & Furmanski P. Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 1995; 373:721-4.
36. Penco S, Pastorino S, Bianchi-Scarra G, Garre C. Lactoferrin down-modulates the activity of the granulocyte macrophage colony-stimulating factor promoter in interleukin-1 beta-stimulated cells. J Biol Chem 1995; 270:12263-8.
37. Brandenburg K, Jurgens G, Muller M, Fukuoka S, Koch MH. Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. Biol Chem 2001; 382:1215-25.
38. Regoeczi E, Chindemi PA, Debanne MT, Prieels JP. Lactoferrin catabolism in the rat liver. Am J Physiol 1985; 248:G8-14.
39. Byrd TF & Horwitz MA. Lactoferrin inhibits or promotesLegionella pneumophila intracellular multiplication in nonactivated and interferon gamma-activated human monocytes depending upon its degree of iron saturation. Iron-lactoferrin and nonphysiologic iron chelates reverse monocyte activation against Legionella pneumophila. J Clin Invest 1991; 88:1103-12.
40. Sorimachi K, Akimoto K, Hattori V, Ieri T, Niwa A. Activation of macrophages by lactoferrin: secretion of TNF-α, IL-8 and NO. Biochem Med Biol Int 1997; 43:79-87.
41. Actor JK, Hwang S-A, Olsen M, Zimecki M, Hunter RL Jr, Kruzel ML. Lactoferrin immunomodulation of DTH response in mice. Int Immunopharmacol 2002; 2:475-86.
42. Zimecki M & Machnicki M. Lactoferrin inhibits the effector phase of delayed type hypersensitivity to sheep erythrocytes and inflammatory reactions to M. bovis (BCG). Arch Immunol Ther Exp 1994; 42:171-7.
43. Zimecki M, Stepniak D, Szynol A, Kruzel ML. Lactoferrin regulates proliferative response of human peripheral blood mononuclear cells to phytohemagglutinin and mixed lymphocyte reaction. Arch Immunol Ther Exp (Warsz) 2001; 49:147-54.
44. Rook GA & Zumla A. Advances in the immunopathogenesis of pulmonary tuberculosis. Curr Opin Pulm Med 2001; 7:116-23.
45. Sorimachi K, Akimoto K, Hattori Y, Ieiri T, Niwa A. Activation of macrophages by lactoferrin: secretion of TNFα, IL-8 and. Biochem Mol Biol Int 1997; 43:79-87.
46. Nishimoto N, Yoshizaki K, Tagoh H et al. Elevation of serum interleukin 6 prior to acute phase proteins on the inflammation by surgical operation. Clin Immunol Immunopathol 1989; 50:399-401.
47. Haupt W, Zirngibl H, Stehr A, Riese J, Holzheimer RG, Hohenberger W. Tumour necrosis factor-alpha and interleukin-10 production in septic patients and the regulatory effect of plasma. Eur J Surg 1999; 165:95-100.
48. Beutler B & Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316:379-85.
49. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 14:355-7.
50. Fisher CJ Jr, Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. Th Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334:1697-702.
51. Nadler EP & Ford HR. Regulation of bacterial translocation by nitric oxide. Pediatr Surg Int 2000; 16:165-8.
52. Zagulski T, Zimecki M, Kruzel ML. Is nitric oxide involved in the protective effect against E. coli infection generated by lactoferrinin vivo? Excerpta Medica International Congress Series. Shimazaki K, Tsuda H, Tomita M et al., eds. Proceedings of the 4th International Congress on Lactoferrin. Elsevier Sciences, Tokyo, 2000; 137-146.
53. Tunctan B, Uludag O, Altug S, Abacioglu N. Effects of nitric oxide synthase inhibition in lipopolysaccharide-induced sepsis in mice. Pharmacol Res 1998; 38:405-11.
54. Qiu Z, Strickland DK, Hyman BT, Rebeck GW. Alpha2-macroglobulin enhances the clearance of endogenous soluble beta-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. J Neurochem 1999; 73:1393-8.
55. Zhang GH, Mann DM, Tsai CM. Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect Immun 1999; 67:1353-8.
56. Tomita M, Yamauchi K, Teraguchi S, Hayasawa H. Host defensive effects of orally administered bovine lactoferrin. Adv Exp Med Biol 1998; 443:189-97.